Q: Can I negotiate a lower GLP-1 cost using these savings numbers?

With self-insured employer plans, yes — HR benefits teams increasingly factor avoided-cost analyses into coverage decisions. Direct pharmacy negotiation rarely moves the needle. The strongest lever is an actuarial analysis showing net-positive ROI at the plan level; HR consultants can often produce one.

Q: What medications might I taper or discontinue?

Antihypertensives often reduce with 5–10 mmHg systolic drop per 10 kg lost. Many T2D patients reduce insulin 20–30% and discontinue sulfonylureas. PPI use often decreases as reflux resolves. Statins typically stay (LDL only drops ~5 mg/dL on semaglutide). NSAID reliance often decreases as knee/joint pain improves.

Q: Are HSA dollars effectively worth more given these savings?

Yes — every pre-tax dollar spent on GLP-1 through an HSA saves federal income tax + FICA (~30% effective savings in most brackets). Combine that with avoided medical costs and the economics are meaningfully better than cash pay. See the HSA/FSA tool for the full math.

Q: What about FLOW (kidney) and STEP-HFpEF (heart failure) data?

FLOW (semaglutide 1 mg in T2D+CKD): 24% reduction in composite kidney failure / ≥50% eGFR loss / kidney or CV death. Dialysis costs $90,000–$110,000/year — deferring by 2–4 years is a major expected-value saving. STEP-HFpEF: improved KCCQ score by 7–9 points in obese HFpEF patients; reduced hospitalization. If you have CKD or HFpEF, the 'health savings' math often dominates the weight-loss calculus.

Q: Where does the math fall apart?

Three caveats. (1) Baseline risk must be real — no pre-diabetes means no T2D avoidance savings. (2) Durability depends on staying on the drug; STEP 4 showed regain post-withdrawal. (3) ICER estimated semaglutide at ~$237K per QALY at list price — above the $150K threshold. Discounted self-pay (LillyDirect $349/mo) or insured copays shift ICER toward favorable.

Question 1

How do I know if my pre-diabetes will actually progress without treatment?

Accepted Answer

Baseline A1C, fasting glucose, and family history are the main predictors. A1C ≥ 6.0% progresses at roughly 10%/year; 5.7–5.9% at 4–6%/year. Your PCP can run a risk calculator. The Diabetes Prevention Program (DPP) data is the reference standard — metformin cut progression 31%, lifestyle cut it 58%, GLP-1s appear to cut it 60–73% in STEP 3.

Question 2

Does the cardiovascular benefit require Wegovy specifically?

Accepted Answer

SELECT was semaglutide 2.4 mg (Wegovy dose). Ozempic (semaglutide up to 2 mg for T2D) has partial read-through but isn't labeled for CV risk reduction in patients without diabetes. Tirzepatide has ongoing CVOTs (SURPASS-CVOT, SURMOUNT-MMO) — no definitive answer yet. If CV risk is the primary indication, Wegovy is the labeled choice.

Question 3

What does SURMOUNT-OSA actually show?

Accepted Answer

Tirzepatide 10/15 mg in adults with moderate-to-severe OSA + obesity reduced AHI by 25–30 events/hour at 52 weeks vs 5–6 on placebo. About 42% of tirzepatide patients saw AHI resolve to < 5 events/hour — functionally curing OSA in the trial. FDA approved Zepbound for moderate-to-severe OSA in obese adults in December 2024, opening a new PA path.

Question 4

Can I negotiate a lower GLP-1 cost using these savings numbers?

Accepted Answer

With self-insured employer plans, yes — HR benefits teams increasingly factor avoided-cost analyses into coverage decisions. Direct pharmacy negotiation rarely moves the needle. The strongest lever is an actuarial analysis showing net-positive ROI at the plan level; HR consultants can often produce one.

Question 5

What medications might I taper or discontinue?

Accepted Answer

Antihypertensives often reduce with 5–10 mmHg systolic drop per 10 kg lost. Many T2D patients reduce insulin 20–30% and discontinue sulfonylureas. PPI use often decreases as reflux resolves. Statins typically stay (LDL only drops ~5 mg/dL on semaglutide). NSAID reliance often decreases as knee/joint pain improves.

Question 6

Are HSA dollars effectively worth more given these savings?

Accepted Answer

Yes — every pre-tax dollar spent on GLP-1 through an HSA saves federal income tax + FICA (~30% effective savings in most brackets). Combine that with avoided medical costs and the economics are meaningfully better than cash pay. See the HSA/FSA tool for the full math.

Question 7

What about FLOW (kidney) and STEP-HFpEF (heart failure) data?

Accepted Answer

FLOW (semaglutide 1 mg in T2D+CKD): 24% reduction in composite kidney failure / ≥50% eGFR loss / kidney or CV death. Dialysis costs $90,000–$110,000/year — deferring by 2–4 years is a major expected-value saving. STEP-HFpEF: improved KCCQ score by 7–9 points in obese HFpEF patients; reduced hospitalization. If you have CKD or HFpEF, the 'health savings' math often dominates the weight-loss calculus.

Question 8

Where does the math fall apart?

Accepted Answer

Three caveats. (1) Baseline risk must be real — no pre-diabetes means no T2D avoidance savings. (2) Durability depends on staying on the drug; STEP 4 showed regain post-withdrawal. (3) ICER estimated semaglutide at ~$237K per QALY at list price — above the $150K threshold. Discounted self-pay (LillyDirect $349/mo) or insured copays shift ICER toward favorable.

Downstream Health Savings on GLP-1 in 2026 — 10-Year Avoided-Cost Estimator

Your inputs

Results

Why the cost conversation misses 50% of the picture

The big three: T2D prevention, ASCVD reduction, OSA resolution

Medications you may taper or discontinue

Running the numbers for three scenarios

Frequently asked questions